Document is current
Any future updates will be listed below
-
Authors
Dröge, Leif Hendrik
Hennies, Steffen
Lorenzen, Stephan
Conradi, Lena-Christin
Quack, Henriette
Liersch, Torsten
Helms, Christian
Frank, Miriam Alice
Schirmer, Markus Anton
Rave-Fränk, Margret
Beißbarth, Tim
Wolff, Hendrik Andreas
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (33996666, 33996666, 33996666)
- License Information
-
More Information
Article History
Received: 11 June 2020
Accepted: 15 February 2021
First Online: 4 March 2021
Ethics approval and consent to participate
: Patients were recruited from three different prospective clinical trials (CAO/ARO/AIO-04 [EudraCT no.: 2006–002385-20, []], TransValid-KFO179/GRCSG-A [DRKS-ID: DRKS00003659] and TransValid-KFO179/GRCSG-B [EudraCT no.: 2011–004228-37]). The Ethics Committee at the University of Göttingen approved the study, and all patients gave informed consent in written form.
: Not applicable.
: The co-author L.C.C. is a member of the editorial board of BMC cancer. Beyond, the authors declare that they have no competing interests.
